
Eloralintide vs Cagrilintide: Trials, Side Effects and Status


Eloralintide and cagrilintide are investigational medicines that target amylin signaling, a pathway involved in fullness and appetite. Both have produced weight loss in clinical trials, but the evidence does not establish which is better for a particular person. They have not been compared in a human head-to-head trial in the evidence reviewed here, and neither should be treated as an approved alternative to an existing prescription.
The useful comparison is about research design, mechanism, tolerability, and unanswered questions. It is not a shopping guide for research peptides. If you are considering treatment now, a discussion of medical weight-management options can address your needs without assuming an experimental drug will be the answer.
What are eloralintide and cagrilintide?
Amylin is a hormone released by the pancreas with insulin after eating. It contributes to the body's coordination of food intake and meal-related glucose handling. Amylin-based medicines aim to extend or strengthen parts of that signaling. They are different from drugs that activate the glucagon-like peptide-1, or GLP-1, receptor.
Eloralintide is designed as a selective amylin receptor agonist. Cagrilintide is a long-acting amylin analog with a different receptor activity profile. That distinction is scientifically interesting, but receptor selectivity is not a patient outcome. A medicine still needs human trials to establish how well it works and which adverse effects occur.
Do not read “different pathway” as “no overlapping side effects.” The drugs can affect related aspects of eating and digestion even though they do not activate precisely the same receptors. Conversely, using more receptor targets does not automatically make treatment more effective or appropriate.
Our overview of GLP-1 treatment support can help you separate established clinical care from pipeline research. The exact product, formulation, and indication matter more than the broad label “weight-loss peptide.”
Eloralintide vs cagrilintide: weight-loss trial results

Lilly's phase 2 eloralintide study involved 263 adults with obesity, or overweight with a weight-related condition, without type 2 diabetes. At 48 weeks, the sponsor reported average reductions of 9.5% to 20.1% across treatment groups, compared with 0.4% for placebo, using an analysis estimating outcomes with continued treatment.
A separate Lancet phase 2 trial studied cagrilintide over 26 weeks in adults without diabetes. Its treatment-adherence analysis reported average weight reductions of 6.0% to 10.8% across studied groups, versus 3.0% with placebo. These numbers describe different studies, not a contest conducted under identical conditions.
The first study ran longer. Its participants, treatment schedules, comparison groups, and analysis choices also differed. Subtracting the largest cagrilintide percentage from the largest eloralintide percentage would create a numerical difference, but it would not estimate the treatment advantage of one over the other.
There is another distinction: cagrilintide alone is not CagriSema. CagriSema combines cagrilintide with semaglutide. Results for the combination cannot be credited entirely to cagrilintide, just as combination results for eloralintide with tirzepatide cannot be described as eloralintide-alone outcomes.
Newer cagrilintide evidence from REDEFINE 1
REDEFINE 1 also included a cagrilintide-alone arm. At 68 weeks, the treatment-policy analysis estimated 11.5% weight reduction with cagrilintide and 3.0% with placebo. This adds longer-duration evidence; it still does not compare cagrilintide with eloralintide.
Read the study question before the percentage
A useful study summary should identify who participated, what they received, the comparator, the duration, and the analysis. Ask whether the result estimates what would happen if everyone stayed on treatment, or includes the consequences of stopping treatment. Both questions matter, but they are different questions.
Also look beyond the mean. An average does not show the full range of response. Some participants may lose more, some less, and some may stop treatment. A personal goal should therefore be discussed as a health objective with a monitoring plan, not calculated directly from a press-release percentage.
Eloralintide and cagrilintide side effects
The available studies do not establish a reliable human tolerability ranking between these two medicines. Gastrointestinal symptoms occurred in cagrilintide trials. The eloralintide phase 2 report also described gastrointestinal symptoms and fatigue, with differences across treatment groups and escalation approaches.
This is why “amylin therapy” should not be presented as a guaranteed way to avoid nausea experienced on a GLP-1 medicine. A new mechanism could eventually offer useful alternatives for some people, but that possibility is not proof that someone who struggled with one drug will tolerate the other.
To interpret tolerability, separate three measures: how many people had a symptom, how severe or persistent it was, and how many stopped treatment because of it. A frequent mild symptom and an uncommon serious reaction are not interchangeable. A report that symptoms were usually mild or moderate does not mean they were easy for every participant to manage.
If you already take a prescribed medicine, record symptoms and discuss them with your clinician. Do not use a trial's treatment schedule as instructions for switching or combining products. Persistent vomiting, inability to keep fluids down, or severe abdominal pain requires prompt medical assessment rather than waiting for a routine weight check.
What about fullness, food noise, and eating enough?
Feeling satisfied with a smaller meal can be useful. Being unable to eat enough to function well is a different outcome. The goal is not to eliminate every hunger signal or make food unpleasant.
It can help to describe your concern more precisely: finishing meals without satisfaction, becoming hungry again quickly, thinking repeatedly about food, or eating in response to stress. Our guide to food noise explores one part of that picture. These experiences can overlap, and none alone proves a particular hormone deficiency.
A careful conversation should also distinguish emotional eating from physical hunger. A medication mechanism does not explain every eating pattern or replace appropriate psychological support. Recurrent loss of control, severe restriction, or distress around food deserves individual assessment.
Reduced appetite also needs a practical nutrition plan. Ask how to maintain food variety, adequate intake, and tolerable meal patterns if appetite changes. Nutritional counseling and coaching can support that discussion without making an experimental product part of the plan.
Can either drug be matched to a specific patient profile?
There is no established clinical rule that a particular appetite pattern, body shape, or routine test identifies the better choice between eloralintide and cagrilintide. Research into treatment matching is promising, but it should not be sold as a precise prediction where evidence is incomplete.
Several questions would be important if either product becomes available through an approved pathway: Does the studied population resemble the patient? Are there relevant contraindications or interactions? Is there evidence for the health outcome that matters most? Can the person continue treatment, attend follow-up, and afford the overall care plan?
For example, a hypothetical person who has stopped previous medication because of persistent vomiting would need a careful tolerability discussion. A different person with satisfactory weight and health progress on an established treatment may have little reason to change simply because a new trial reports a larger average.
Neither example identifies a drug winner. They show why the same headline can have different relevance for different people.
Are either of these medicines available for routine treatment?
Start with a record of your current health priorities and treatment experience. Note previous medicines, benefits, adverse effects, reasons for stopping, and practical barriers such as cost or follow-up access. Include all supplements and products marketed as peptides in the discussion.
If progress has slowed, bring enough information to evaluate the pattern. Our weight-loss plateau guide explains why a sustained trend deserves a different response from a few unchanged weigh-ins. A plateau does not demonstrate that you need an additional experimental receptor target.
Choose a measurement approach that is useful and emotionally manageable. Our guidance on weighing frequency can help you plan the conversation. Weight is one measure; symptoms, daily function, nourishment, and relevant clinical markers also belong in a review.
Ask the clinician to explain the current options and the reason for the proposed plan. If a research study interests you, discuss legitimate trial participation, eligibility, visits, randomization, and what happens if side effects occur. A study registration is not a guarantee of benefit or an approval to self-administer a product.
Why online peptide listings are a separate issue
An online vial labeled with a drug name is not evidence that it matches the material used in a clinical trial. Product identity, concentration, sterility, storage, and instructions can all be uncertain. A seller's certificate cannot substitute for an approved medicine and an appropriate clinical pathway.
The FDA's warning about unapproved weight-loss drugs specifically addresses cagrilintide and other investigational products. Do not infer that a product is acceptable for personal use because a seller calls it “research only,” or because someone shares an apparent success story.
Maryland Trim Clinic in Laurel, MD
At Maryland Trim Clinic, we support individualized weight-management assessment and follow-up. We can help you put research headlines into the context of your current health, previous treatment experience, and practical care needs.
The immediate decision is whether your present plan is suitable and sustainable. Emerging amylin therapies may expand future options, but the evidence supports curiosity and careful evaluation, not a universal ranking.
This article provides general education and does not replace individual medical advice.
Frequently Asked Questions
Is eloralintide proven to work better than cagrilintide?
No. Comparing percentages from separate trials does not establish superiority. A suitable direct comparison would be needed to answer that question reliably.
Is CagriSema another name for cagrilintide?
No. CagriSema combines cagrilintide and semaglutide. Evidence for the combination must be distinguished from cagrilintide-alone research.
Does an amylin drug avoid GLP-1 side effects?
Not necessarily. Different receptor activity does not guarantee freedom from gastrointestinal symptoms or establish suitability after a previous medication reaction.
Can a trial result tell me how much weight I will lose?
No. It describes a group under defined study conditions. Individual outcomes, tolerability, and the ability to remain on treatment vary.
Talk Through Your Weight-Loss Options
If you’re comparing new treatment research or wondering what fits your current plan, our team can help you review your options and discuss next steps.